8-K: PDS Biotech's Combination Therapy for Metastatic Colorectal Cancer Receives FDA Clearance

PDS Biotechnology announces FDA clearance of its IND application for a combination therapy targeting MUC1-positive metastatic colorectal cancer.

Summary

• PDS Biotechnology Corporation has received FDA clearance for its Investigational New Drug (IND) application to evaluate a combination of Versamune MUC1 and PDS01ADC for treating MUC1-positive unresectable, metastatic colorectal carcinoma (mCRC) in patients who have failed previous treatments.
• The Phase 1/2 clinical trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
• Versamune MUC1 targets mCRC tumors that are MUC1-positive, specifically in Proficient Mismatch Repair/Microsatellite Stable mCRC, which represents 95% of mCRC patients.
• U.S. Patent #12,201,685 covers methods of using combinations of the Versamune platform and various immunocytokines, including PDS01ADC.

Sentiment

Score: 7

Explanation: The announcement is positive due to the FDA clearance, but tempered by the early stage of the clinical trial and the inherent risks in drug development.

Positives

• FDA clearance of the IND application allows PDS Biotech to proceed with clinical trials for a novel cancer therapy.
• Collaboration with the NCI provides resources and expertise for the clinical trial.
• The therapy targets a specific subset of colorectal cancer patients (MUC1-positive) who have limited treatment options.
• The Versamune platform shows potential to expand beyond HPV-related cancers.

Risks

• The success of the therapy is dependent on the outcome of clinical trials.
• The company's future is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• The company has a limited operating history in its current line of business, which makes it difficult to evaluate the company's prospects.

Future Outlook

The company plans to support the NCI investigation of the therapy while remaining focused on its VERSATILE-003 Phase 3 clinical trial in HPV16-positive head and neck squamous cell carcinoma.

Management Comments

• Kirk Shepard, M.D., PDS Biotech's Chief Medical Officer, stated that targeting MUC1 with an immunotherapy that elicits a strong and durable tumor-infiltrating T-cell response could represent a major advancement in cancer treatment.
• Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, noted that the IND clearance of Versamune MUC1 marks progress for the Versamune platform and its potential to expand beyond HPV-related cancers.

Industry Context

This announcement positions PDS Biotech in the competitive landscape of immunotherapy companies, particularly those focused on developing targeted therapies for solid tumors. The collaboration with the NCI is a significant endorsement of the company's technology.

Comparison to Industry Standards

• Many companies are developing immunotherapies for colorectal cancer, including checkpoint inhibitors and cell therapies.
• PDS Biotech's approach of targeting MUC1, a protein overexpressed in many solid tumors, differentiates it from other immunotherapies.
• The collaboration with the NCI is similar to other partnerships between biotech companies and government research institutions to accelerate drug development.

Stakeholder Impact

• Positive for shareholders due to the advancement of the company's pipeline.
• Potential benefit for patients with MUC1-positive metastatic colorectal cancer who have failed previous treatments.
• Opportunity for the NCI to contribute to the development of a novel cancer therapy.

Next Steps

• Initiate Phase 1/2 clinical trial evaluating the combination of Versamune MUC1 + PDS01ADC in recurrent/metastatic colorectal cancer, led by the National Cancer Institute (NCI).

Key Dates